The Financial, Environmental and Social Profit and Loss (FES P&L) approach aims to measure the social and economic impact of Novartis’ social activities on local communities.
AstraZeneca has a new pricing policy for its respiratory and cardiovascular disease products in certain key out-of-pocket markets in scope, based on an ability-to-pay analysis.
AstraZeneca has developed an internal governance structure for its Healthy Heart Africa programme, consisting of a Global Advisory Board and National Steering Committee.
Merck KGaA and Novo Nordisk are realigning their access-related targets and access initiatives with the Sustainable Development Goals (SDGs).
Bayer co-founded an International Society of Pharmacovigilance Special Interest Group to develop and share innovative risk minimisation methods and tools.
Gilead and Bristol-Myers Squibb take the first moves, from companies in scope of the Access to Medicine Index 2016, outside non-exclusive voluntary licensing in HIV/AIDS.
Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.